A recent study showed that the risk for heart failure is particularly high in the presence of CKD [67], thus patients with CVD, CKD and heart failure should be treated with SGLT2 inhibitors but not with DPP-4 inhibitors [66]. This evidence concerns the gene SLC5A2 and chronic kidney disease.